Skip to main content
Premium Trial:

Request an Annual Quote

TJ Johnson, John Lubniewski

HTG Molecular Diagnostics has announced that TJ Johnson, the firm's current CEO, will assume the role of executive chairman of its board of directors. John Lubniewski, HTG's president and chief operating officer, will succeed Johnson as CEO. In addition, Ann Hanham will assume the role of lead independent director at the end of Q1 2019.

Lubniewski has served as HTG's president and COO since April 2018, joining the firm in 2011 as chief business officer. Before HTG, Lubniewski served in several leadership roles at Ventana, including senior VP and life cycle leader for platforms and clinical assays, as well as head of global marketing. Prior to Ventana, Lubniewski worked at Corning for over a decade in a variety of roles.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.